August 2020 — With offices in Cambridge, MA, Celsius' mission is to develop life-saving medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.

February 2020 — With offices in Cambridge, MA, Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.

January 2020 — With US offices in San Diego and South San Francisco, Shouti Pharmaceuticals will be using R&D Logic's R&D Time to manage and prioritize portfolio resources.

December 2019 — With offices in Ottawa and New York City, Turnstone Biologics' mission is to deliver breakthrough viral immunotherapies to improve survival for patients with cancer.

June 2019 — Located in San Diego, CA, Turning Point Therapeutics has created a new generation of therapies that are different from the conventional kinase inhibitors. Their compact molecules are potentially more potent and selective medicines that also hold promise to prevent and overcome resistance.

March 2019 — Located in Cambridge, MA, Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer.

August 2018 — Located in Vancouver, BC, Ondine is focused on the development and commercialization of their patented light activated technology, photodisinfection. Photodisinfection provides rapid antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

July 2018 — Located in Cambridge, MA, RA Pharma is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system.

June 2018 — Located in Richmond, CA, Sangamo Therapeutics believes, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases.

March 2018 — Located in Redwood City, CA ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors.

October 2017 — Founded in 1994, and located in South San Francisco, CA, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

July 2017 — Located in San Francisco, CA Jaguar Animal Health is developing a pipeline of prescription drug product candidates and non-prescription products to address unmet needs in animal health.

May 2017 — Located in Cambridge, MA, Warp Drive Bio operates on the core principle that nature is the most powerful inventor of new drugs, unconstrained by the boundaries of modern science.

December 2016 — Located in Mountain View, CA, IGM Biosciences is dedicated to helping patients world-wide by creating and developing novel IgM and IgA antibodies which improve the treatment of cancer and infectious diseases.

September 2016 — Located in Baltimore, MD, Cerecor Inc. joins the growing list of Biotech and Pharmaceutical companies convinced that doing business with a software company dedicated to life sciences is the right choice. Cerecor Inc. is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders.

July 2016 — Located in Cambridge, MA, Intellia Therapeutics is the most recent Biotech company to recognize R&D Logic's unique life sciences specialization. Intellia's combination of deep scientific expertise and clinical development experience, along with their leading intellectual property portfolio, puts them in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.

April 2016 — Located in Cambridge, MA, Spero Therapeutics is the latest life science company to select R&D Logic's Life Sciences specialty solution to manage their R&D intensive company. Spero's mission is to develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease.

April 2016 — Located in Newton, MA, Karyopharm Therapeutics is the latest life science company in this explosive Biotech hub to select the R&D Logic solution to manage their R&D intensive company. Karyopharm's mission is to discover and develop first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

March 2016 — Located in San Bruno, CA, Balance Therapeutics has selected R&D Logic's Life Sciences specialty solution to manage their R&D intensive company. Balance is focused on developing therapeutics to address neurological disabilities resulting from excess inhibition of the brain.

January 2016 — Located in San Francisco, CA, Nurix has selected R&D Logic's Life Sciences specialty solution to manage their R&D intensive company. Nurix is passionate in its mission of pioneering the development of small molecules that modulate the ubiquitin proteasome system (UPS) for improvement of human health.